OC

Knowledge OS
登录 注册
鹦鹉螺口语
Iambic debuts next version of AI model Enchant, driving new way for drug R&D
2025-05-05 12:30:00 · 英文原文

Iambic debuts next version of AI model Enchant, driving new way for drug R&D

作者：May 5, 2025 08:30 AM EDTUpdated 09:24 AM AI

Tom Miller, Iambic Therapeutics CEO

May 5, 2025 08:30 AM EDTUpdated 09:24 AM

Andrew Dunn

Senior Biopharma Correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ENDPOINTS CAREERS

关于《Iambic debuts next version of AI model Enchant, driving new way for drug R&D》的评论

暂无评论

发表评论

摘要

Tom Miller, CEO of Iambic Therapeutics, is the focus of a recent article. The piece requires a subscription for full access and includes an opportunity to apply for a Uro-Oncology Business Manager position at ImmunityBio, Inc., which allows for remote work.

相关新闻

相关讨论